- Allergy
- Aspergillosis
- B19 parvovirus
- Bacterial infections
- Blastomycosis
- Cancers - overview
- Candidiasis
- Cardiomyopathy
- Coccidioidomycosis
- Cryptococcus
- Cryptosporidiosis
- Cytomegalovirus (CMV) - overview
- Cytomegalovirus (CMV) - key research on treatment
- Cytomegalovirus (CMV) - key research on prophylaxis
- Cytomegalovirus (CMV) - references
- Depression
- Diabetes
- Entamoeba histolytica
- Giardia lamblia
- Gingivitis
- Guillain-Barré syndrome
- Gynaecomastia (breast enlargement)
- Hairy leukoplakia
- Hepatitis A
- Hepatitis B
- Hepatitis C - overview
- Hepatitis C - key research
- Hepatitis C - references
- Herpes simplex
- Histoplasmosis
- HIV-associated dementia - overview
- HIV-associated dementia - key research
- HIV-associated dementia - references
- HIV-associated salivary disease
- Hodgkin's disease
- Human herpes virus 6
- Human papilloma virus
- Isosporiasis
- Kaposi's sarcoma - overview
- Kaposi's sarcoma - key research
- Kaposi's sarcoma - references
- Lactic acidosis / acidaemia
- Leishmaniasis
- Lung cancer
- Lymphocytic interstitial pneumonitis
- Malaria
- Microsporidiosis
- Molluscum contagiosum
- Multicentric Castleman's disease
- Mycobacterium avium intracellulare (MAI) - overview
- Mycobacterium avium intracellulare (MAI) - key research
- Mycobacterium avium intracellulare (MAI) - references
- Mycobacterium haemophilum
- Mycobacterium kansasii
- Neuropathy
- Neutropenia
- Non-Hodgkin's lymphoma
- Osteonecrosis
- Osteoporosis
- Pancreatitis
- Pelvic inflammatory disease
- Penicilliosis
- Persistent generalised lymphadenopathy
- Pneumocystis pneumonia (PCP) - overview
- Pneumocystis pneumonia (PCP) - prevention & prophylaxis key research
- Pneumocystis pneumonia (PCP) - treatment key research
- Pneumocystis pneumonia (PCP) - references
- Progressive multifocal leukoencephalopathy (PML)
- Psoriasis
- Pulmonary arterial hypertension
- Q fever
- Renal (kidney) disease
- Salmonellosis
- Schistosomiasis and other worm and fluke infections
- Seborrhoeic dermatitis
- Syphilis
- Testicular cancer
- Testosterone deficiency
- Thrombocytopenia
- Thrombotic thrombocytopenic purpura
- Tinea
- Toxoplasmosis - overview
- Toxoplasmosis - treatment key research
- Toxoplasmosis - prophylaxis key research
- Toxoplasmosis - references
- Tuberculosis
- Ulcers
- Vacuolar myelopathy
- Varicella zoster virus
- Wasting syndrome - overview
- Wasting syndrome - key research
- Wasting syndrome - references
Isosporiasis
Isospora belli is a parasite which belongs to the Coccidia family, which also include Cryptosporidium and Toxoplasma gondii. It is most commonly found in tropical and subtropical climates.
It is probably transmitted by oral-faecal contact from person-to-person and by drinking water contaminated by faeces carrying the parasite; unlike Cryptosporidium, it does not appear to be transmitted from animal-to-human. It can infect the intestines of HIV-positive people, causing the illness known as isosporiasis (sometimes called coccidiosis).
Symptoms and diagnosis
Isosporiasis causes symptoms very similar to those of cryptosporidiosis watery diarrhoea, cramping pains in the abdomen and weight loss.
It is diagnosed by testing a sample of stool (faeces) for the presence of the parasite.
Treatment
Co-trimoxazole (one double-strength tablet 4 times a day for 10 days, then twice a day for 3 weeks) is effective against isosporiasis; the diarrhoea usually improves within a couple of days of starting treatment. It also has a preventive effect, so people who are receiving co-trimoxazole as PCP prophylaxis are at low risk of developing isosporiasis.
For people who cannot tolerate co-trimoxazole, pyrimethamine plus folinic acid, pyrimethamine plus sulphadoxine, metronidazole or furazolidone may be offered. Maintenance therapy (secondary prophylaxis) with co-trimoxazole, pyrimethamine alone, pyrimethamine plus sulphadoxine or metronidazole is necessary to try to prevent recurrence.
Key research
Pape successfully treated 32 patients with co-trimoxazole (160mg/800mg by mouth four times daily for 10 days). 22 patients were randomized to receive maintenance therapy of either co-trimoxazole (160mg/800mg three times a week) or sulphadoxine-pyrimethamine (500mg/25mg weekly). One patient receiving co-trimoxazole relapsed three weeks after initiation of maintenance. All others remained asymptomatic. 5/10 on placebo relapsed 1.5 months after initial treatment. Weiss successfully treated two AIDS patients, unable to tolerate sulphonamides, for isosporiasis with pyrimethamine (50-75mg by mouth every day) and folinic acid (10mg by mouth every day); recurrence was prevented by maintenance treatment with pyrimethamine (25mg by mouth every day) and folinic acid (5mg by mouth every day). Kayembe treated 8 AIDS patients with abdominal pains and Isospora belli diarrhoea with 200mg diclazuril for 7 days. The abdominal pains and cramps disappeared in all 8 patients. All patients were negative for I. belli at the first check up. In 1 patient severe diarrhoea persisted.
References
de Hovitz JA et al. Clinical manifestations of Isospora belli patients with AIDS. NEJM 315: 87-90, 1986. Kayembe K et al. Diclazuril for Isospora belli infection in AIDS. Lancet i: 1397-1398, 1989. Pape JW et al. Treatment and prophylaxis of Isospora belli infection in patients with the acquired immune deficiency syndrome. NEJM 320(16): 1044-1047, 1989. Weiss LM et al. Isospora belli infection: treatment with pyrimethamine. Ann Int Med 109(6): 474-75, 1988.
latest aidsmap news
- Large HIV vaccine study will not go ahead
- Swiss court rules all people with HIV can be criminally liable for transmission, even if untested
- Genital shedding of HIV in women with undetectable viral load: less of it, but still happening
- Microbicides could prevent more infections in men than in women
- Knowledge of STIs poor in rural Tanzania - associated with risky sex and infection with HIV
- HIV treatment effective for infants in resource-limited settings
- Need for vigilance: two cases of abacavir allergy despite pre-treatment screening all-clear
- One third of people with HIV have experienced sexual difficulties in the past month
- Differing causes of lung infections in HIV-positive patients: implications for diagnosis and treatment
- Roche to halt HIV drug research
